secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001125345-24-000140
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics receives $100M milestone payment from Incyte for retifanlimab collaboration
--------------------------------------------------------------------------------

- MacroGenics and Incyte amended their 2017 collaboration agreement, deeming milestones achieved and triggering a $100M payment to MacroGenics.
- MacroGenics confirms cash runway guidance into 2026, supported by the $100M milestone plus expected partner payments and product revenues.
- Total milestones achieved from Incyte now reach $215M since the initial 2017 collaboration.
- Retifanlimab (ZYNYZ) is a PD-1 inhibitor for Merkel cell carcinoma, originally developed by MacroGenics and licensed to Incyte.
- MacroGenics remains eligible for up to $210M in development/regulatory milestones and $330M in commercial milestones from Incyte.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534524000140/0001125345-24-000140-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534524000140/mgnx-20240724.htm
  HTML page:      https://secwatch.observer/filing/0001125345-24-000140

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer